Entyvio vs Stelara for Crohn's Disease: Which Is Better?

Entyvio and Stelara are two of the most common biologics prescribed when an anti-TNF like Humira or Remicade stops working for Crohn's disease. Both are alternatives to TNF blockade, but they take very different mechanistic paths to quiet gut inflammation. Entyvio is gut-selective. Stelara targets a cytokine pathway that operates throughout the body but is especially active in the gut. For patients weighing a second-line choice, the decision often hinges on infection risk, onset of action, and long-term safety. This guide walks through the evidence patients need to make an informed entyvio vs stelara crohn's decision with their gastroenterologist.

Gut-Selective vs IL-12/23 Mechanism

Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed intestinal tissue, it quiets gut inflammation without meaningfully suppressing the immune system elsewhere. Stelara (ustekinumab) binds the p40 subunit shared by interleukin-12 and interleukin-23, two cytokines further upstream in the inflammatory cascade. By blocking IL-12/23, Stelara dampens T-cell subsets that drive inflammation both in the gut and in extraintestinal tissues. The vedolizumab vs ustekinumab distinction shapes nearly every downstream difference. Entyvio has a narrower footprint confined to the gut. Stelara acts more broadly but still avoids the systemic TNF blockade that raises infection risk with anti-TNFs.

Efficacy in Biologic-Experienced Crohn's Patients

Most patients weighing these two drugs have already failed an anti-TNF, and that context matters because efficacy drops in the second-line setting. A 2021 systematic review and network meta-analysis found that in patients with prior anti-TNF exposure, ustekinumab ranked higher than vedolizumab for clinical remission and response at induction. The EVOLVE real-world cohort of biologic-naive patients reported similar 12-month clinical outcomes across the two drugs and higher drug persistence for vedolizumab, but biologic-naive data does not always translate to anti-TNF experienced patients. A 2022 comparative observational analysis of anti-TNF experienced Crohn's patients found that ustekinumab produced higher rates of steroid-free clinical remission at one year than vedolizumab, particularly in patients with more severe disease.

Onset of Action and Induction

Stelara tends to work faster than Entyvio in Crohn's. Vedolizumab's label instructs clinicians to wait until week 14 before deciding whether the drug is working, and some patients continue to improve through week 26. Stelara's labeled response assessment point is around week 8 after IV induction, and most patients who are going to respond show symptom improvement within the first two months. For patients with active symptoms who cannot tolerate a long ramp-up, the entyvio vs stelara effectiveness gap in early weeks often tips the decision toward ustekinumab. For patients in a less acute state, Entyvio's slower onset is generally manageable.

Safety and Infection Risk

Both drugs have a favorable long-term safety profile relative to anti-TNFs, but the risk signals differ. Entyvio's gut-selective action produces very low rates of systemic infection. Stelara's infection profile is also low, with a ten-year analysis showing fewer hospitalizations for infection on ustekinumab than on infliximab. A 2024 Swedish registry study of Crohn's patients did flag a higher rate of serious gastrointestinal infections on vedolizumab compared to anti-TNFs, while overall systemic infection rates were lower. Stelara carries a boxed warning for serious infections and rare malignancies. Neither drug requires routine combination therapy with an immunomodulator, which simplifies long-term management. For patients with frequent infections, recurrent respiratory illness, or a personal history of cancer, the entyvio vs stelara side effects comparison often favors whichever drug your GI judges the narrower immune footprint in your specific context.

Dosing and Administration

Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. Stelara uses a single weight-based IV induction dose at week 0, then transitions to a 90 mg subcutaneous injection every 8 weeks that patients give themselves at home, per Janssen's Stelara dosing information. For patients who want the fewest maintenance visits, both drugs share an every-8-week cadence. For patients who want to eliminate infusion center visits after induction, Stelara moves to home-based injection sooner (after a single IV dose) compared to Entyvio's three IV induction doses before SC conversion becomes an option.

Extraintestinal Manifestations and Comorbidities

Patients with extraintestinal manifestations of Crohn's, such as joint pain, psoriasis, or uveitis, often respond better to Stelara than to Entyvio. Ustekinumab has approved indications in plaque psoriasis and psoriatic arthritis, and IL-12/23 blockade addresses inflammation across multiple tissues. Entyvio's gut-selective action means it does not treat extraintestinal disease well. A patient with Crohn's plus moderate plaque psoriasis, for example, usually gets more benefit from Stelara because one drug covers both conditions. A patient without extraintestinal involvement who is prioritizing the narrowest possible immune suppression may lean toward Entyvio.

Choosing With Your GI

There is no single correct answer in the entyvio vs stelara crohn's decision. Stelara tends to win on speed of onset, efficacy in anti-TNF experienced patients, and coverage of extraintestinal disease. Entyvio tends to win on systemic infection risk and the narrowest immune footprint. Your gastroenterologist will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage when making the recommendation. Before starting either drug, ask your GI how response will be measured (and at what week), what side effects warrant a call between visits, and whether therapeutic drug monitoring will be part of your follow-up. A consistent log of bowel movements, abdominal pain, urgency, and any new joint or skin symptoms gives your care team the data to recognize early loss of response before a full flare returns.